Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 10
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
Thyroid Eye Disease · Graves' Orbitopathy
Enrolment: 83 · Results not recorded
A Safety, Tolerability, and Efficacy Study of Veligrotug, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor in Subjects With Thyroid Eye Disease
Thyroid Eye Disease
Enrolment: 113 · Results not recorded
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Thyroid Eye Disease (TED)
Thyroid Eye Disease
Enrolment: 231 · Results not recorded
Phase II Study of Cetuximab With or Without OSI-906, a Dual Insulin-like Growth Factor-1 Receptor and an Insulin Receptor Inhibitor, in Platinum-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Enrolment: 0 · Results not recorded
A Single-Center, Prospective, Randomized, Open-Label, Parallel-Group Study Comparing Sequential Teprotumumab N01 With Intravenous Methylprednisolone After Urgent Orbital Decompression in Patients With Dysthyroid Optic Neuropathy
Thyroid Eye Disease, TED · Graves Ophthalmopathy · Optic Neuropathy
Enrolment: 60 · Results not recorded
A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors
Multiple paediatric solid tumour types
Enrolment: 116 · Results not recorded
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.
Sarcoma
Enrolment: 317 · Results not recorded
A Phase I-II Trial of MK-0646, a Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor, in Combination With Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer
Lung Cancer
Enrolment: 12 · Results not recorded
A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Unspecified Childhood Solid Tumor, Protocol Specific
Enrolment: 34 · Results not recorded
Phase 3b, Multicenter, Open-label, Single-Arm Expanded Access Protocol of TEPROTUMUMAB (HZN-001)
Thyroid Eye Disease · Graves' Orbitopathy
Enrolment not recorded · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseEndotoxin/LPS
Model: Lipopolysaccharide-induced acute lung injury in mice, with parallel in vitro lipopolysaccharide-treated cell experiments
Treatment with the IGF-1 receptor monoclonal antibody lowered lavage cell counts and pro-inflammatory cytokines, reduced histological lung injury and decreased RIP3 and phosphorylated MLKL expression compared with non-treated animals.
Extraction: extract · Supplied extraction confidence: 0.45. Machine-extracted fields require source verification.
